What is Edammo?
Edammo operates at the intersection of advanced biotechnology and precision engineering, utilizing a proprietary framework that integrates physics-based modeling with artificial intelligence. The company is dedicated to the development of first-in-class therapeutic candidates designed to address high-unmet-need conditions, including cardiovascular disease, diabetic complications, and oncology. By shifting the paradigm of traditional drug discovery, Edammo aims to improve global standards of care through data-driven innovation and rigorous scientific methodology. Its market position is defined by a commitment to solving complex biological challenges that have historically eluded conventional pharmaceutical approaches.
How much funding has Edammo raised?
Edammo has raised a total of $15K across 1 funding round:
Debt
$15K
Debt (2021): $15K with participation from PPP
Key Investors in Edammo
PPP
Public-Private Partnership
What's next for Edammo?
With the recent injection of capital, Edammo is poised to advance its pipeline through critical clinical milestones and regulatory pathways. The strategic deployment of these funds will likely focus on scaling research infrastructure, expanding the technical team, and accelerating the transition of lead candidates from the laboratory to human trials. As the company navigates the Series A/B growth stage, the focus remains on achieving operational efficiency and demonstrating the efficacy of its AI-driven platform. Future growth will be contingent upon the successful validation of its drug candidates and the ability to maintain a robust intellectual property portfolio in an increasingly crowded biotech landscape.
See full Edammo company page
